Proteomics International is experienced in delivering quality, accurate results that help progress your research and business.
Accreditation recognises Proteomics Internationals’ ability to consistently achieve technically valid, traceable and reproducible results. In Australia, accreditation is assessed by NATA (the National Association of Testing Authorities). ISO/IEC 17025 is recognised worldwide as the main ISO standard used by testing and calibration laboratories, and is the most widely used laboratory standard for US Federal testing laboratories. ISO/IEC 17025 is used by the FDA’s testing facilities. In 2009, the company’s laboratory was the first facility in the world to receive ISO 17025 accreditation for proteomics services.
The quality of Proteomics International’s technical expertise is demonstrated by its discovery of the protein biomarkers associated with Diabetic Kidney Disease. This discovery is currently being commercialised as a diagnostic and prognostic test for Diabetic Kidney Disease – PromarkerD. Proteomics International’s discovery, and the rigour behind the research phase was sufficiently notable that the world’s leading mass spectrometer manufacturer, AB Sciex , released a Technote using Proteomics International’s research pipeline for Diabetic Kidney Disease to illustrate Biomarker Discovery.